Compare · CAH vs HKPD
CAH vs HKPD
Side-by-side comparison of Cardinal Health Inc. (CAH) and Cellyan Biotechnology Co. Ltd (HKPD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAH and HKPD operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- CAH carries a market cap of $14.83B.
- Over the past year, CAH is up 44.6% and HKPD is down 28.6% - CAH leads by 73.1 points.
- CAH has been more active in the news (2 items in the past 4 weeks vs 1 for HKPD).
- CAH has more recent analyst coverage (25 ratings vs 0 for HKPD).
- Company
- Cardinal Health Inc.
- Cellyan Biotechnology Co. Ltd
- Price
- $199.83-2.42%
- $0.65-12.02%
- Market cap
- $14.83B
- -
- 1M return
- -5.45%
- +0.03%
- 1Y return
- +44.55%
- -28.57%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 2
- 1
- Recent ratings
- 25
- 0
Cardinal Health Inc.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Latest CAH
- SEC Form 4 filed by Hall Patricia Hemingway
- Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings
- Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies
- Amendment: SEC Form SCHEDULE 13G/A filed by Cardinal Health Inc.
- Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2026 on April 30
- Cardinal Health Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cardinal Health Appoints Patricia A. Hemingway Hall as Board Chair
- Cardinal Health Inc. filed SEC Form 8-K: Leadership Update
- Chief Information Officer Greene Michelle D. sold $627,387 worth of shares (2,746 units at $228.47), decreasing direct ownership by 18% to 12,230 units (SEC Form 4)
- Cardinal Health report highlights cost savings and provider confidence in biosimilars
Latest HKPD
- SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
- SEC Form F-1 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
- Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited